Immatics US, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
ACTengine® IMA203 Combined With mRNA-4203
- Conditions
- Cutaneous MelanomaSynovial Sarcoma
- Interventions
- Biological: mRNA-4203
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06946225
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
- Conditions
- Recurrent CancerAdult Solid TumorNeoplasmsRefractory Cancer
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03760952
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Oncology Consultants, Houston, Texas, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Conditions
- Solid Tumor, AdultRefractory CancerRecurrent CancerCancer
- Interventions
- Biological: IMA203 ProductBiological: IMA203 product- flat doseBiological: IMA203CD8 ProductDevice: IMADetect®
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT03686124
- Locations
- 🇺🇸
Massachussettes General Hospital, Boston, Massachusetts, United States
🇺🇸University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
TCR-engineered T Cells in Solid Tumors: IMA202-101
- Conditions
- Solid Tumor, AdultCancerRefractory CancerRecurrent Cancer
- Interventions
- Drug: IMA202 ProductDevice: IMADetect®
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03441100
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
🇩🇪Universitätsklinikum C.-G.-Carus Dresden, Dresden, Saxony, Germany
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
- Conditions
- Recurrent Solid TumorsRefractory Solid TumorsSolid TumorCancer
- Interventions
- Biological: IMA201 ProductDiagnostic Test: IMADetect®
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03247309
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇩🇪Universitätsklinikum Bonn, Venusberg-Campus 1, Bonn, North Rhine-Westphalia, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74, Dresden, Saxony, Germany
ACTolog in Patients With Solid Cancers
- Conditions
- CancerSolid Tumor
- Interventions
- Biological: IMA101 productDiagnostic Test: IMADetect
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02876510
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States